Ambroxol vs CAP-003

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: GBA1/glucocerebrosidase · full Parkinson's Disease pipeline

Ambroxol

Developed by Agyany Pharma Ltd

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT05830396 · Phase 2/3 · status unknown

This is a randomized, placebo-controlled trial with full blinding of participants, care providers, and assessors, using a validated Parkinson's motor rating scale as its primary endpoint. Results have not yet been posted, so whether ambroxol improved motor outcomes compared with placebo is not yet known.

Next expected readout: February 2029 · NCT05778617 (registry estimate)

Reported efficacy

Change from baseline in Montreal Cognitive Assessment score (baseline and week 52); Change from baseline in conversion rate from normal cognitive function (PD-N) to mild cognitive impairment (PD-MCI) and from PD-N or PD-MCI to Parkinson-Dementia (PD-D) (baseline and week 52): Primary (MoCA change at 52 weeks): -0·69 ambroxol vs 0·19 placebo (n=28 per group); mean difference -1·18 (95%CI -2·63 to 0·27, p=0·053); adjusted mean difference -1·05 (95%CI -2·17 to -0·06, p=0·030), significantly worse with ambroxol. (missed)

Result source: NCT05287503

CAP-003

Developed by Capsida Biotherapeutics, Inc.

gene therapy
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmbroxolCAP-003
OFF time, change—Trial running · NCT05778617—Not reported
ON time without troublesome dyskinesia, change—Trial running · NCT05778617—Not reported
UPDRS Part III, change—Trial running · NCT05778617—Not reported
MDS-UPDRS Part II, change—Trial running · NCT05778617—Not reported

OFF time, change

Ambroxol
—Trial running · NCT05778617
CAP-003
—Not reported

ON time without troublesome dyskinesia, change

Ambroxol
—Trial running · NCT05778617
CAP-003
—Not reported

UPDRS Part III, change

Ambroxol
—Trial running · NCT05778617
CAP-003
—Not reported

MDS-UPDRS Part II, change

Ambroxol
—Trial running · NCT05778617
CAP-003
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CAP-003: no structured comparison results are available for Parkinson's Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ambroxol
Primary (MoCA change at 52 weeks): -0·69 ambroxol vs 0·19 placebo (n=28 per group); mean difference -1·18 (95%CI -2·63 to 0·27, p=0·053); adjusted mean difference -1·05 (95%CI -2·17 to -0·06, p=0·030), significantly worse with ambroxol. NCT05287503 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ambroxol's landscape · CAP-003's landscape